The company states: “PROCEPT BioRobotics (PRCT) announced that Aquablation therapy was assigned a Category I code effective January 1, 2026. The 2026 Medicare Proposed Physician Fee Schedule includes payment rates for a new Category I Current Procedural Terminology code related to Aquablation therapy. Category I CPT code 52XX1 will replace Category III CPT code 0421T as the primary code for Aquablation therapy. The new CPT Category I Code 52XX1 was assigned a 2026 national Medicare physician proposed payment of 16.14 total RVUs which translates to an approximate national average of $540, under the 2026 proposed Medicare PFS. By comparison, TURP was assigned 15.82 total RVUs which translate to an approximate national average of $529.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Procept BioRobotics initiated with an Overweight at Stephens
- Procept BioRobotics initiated with a Perform at Oppenheimer
- Positive Outlook for PROCEPT BioRobotics Amid Anticipated CMS Reimbursement and Category 1 Transition
- PROCEPT BioRobotics Elects Board at Annual Meeting
- Buy Rating on PROCEPT BioRobotics: Innovative BPH Solutions and Prostate Cancer Potential Drive Growth Outlook